Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study.

MLA

Wang, Shanshan, et al. “Effectiveness, Safety, and Biomarker Analysis of Lenvatinib plus Toripalimab as Chemo-Free Therapy in Advanced Intrahepatic Cholangiocarcinoma: A Real-World Study.” Cancer Immunology, Immunotherapy, vol. 73, no. 12, Dec. 2024, pp. 1–14. EBSCOhost, https://doi.org/10.1007/s00262-024-03841-z.

APA

Wang, S., Chao, J., Wang, H., Li, S., Wang, Y., Zhu, C., Zhang, N., Piao, M., Yang, X., Liu, K., Xun, Z., Sang, X., Yang, X., Duan, W., & Zhao, H. (2024). Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study. Cancer Immunology, Immunotherapy, 73(12), 1–14. https://doi.org/10.1007/s00262-024-03841-z

Chicago

Wang, Shanshan, Jiashuo Chao, Hao Wang, Shuofeng Li, Yunchao Wang, Chengpei Zhu, Nan Zhang, et al. 2024. “Effectiveness, Safety, and Biomarker Analysis of Lenvatinib plus Toripalimab as Chemo-Free Therapy in Advanced Intrahepatic Cholangiocarcinoma: A Real-World Study.” Cancer Immunology, Immunotherapy 73 (12): 1–14. doi:10.1007/s00262-024-03841-z.